Market research
PCBK.F Sesen Bio, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 2.25
- Dividend yield
- 0.0%
- Beta
- 0.83
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US8177631053
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 2.25
- Dividend yield
- 0.0%
- Beta
- 0.83
About
About Sesen Bio, Inc
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PCBK.F discussion.
5 years, 4 months ago
Sesen Bio, Inc is currently in a long term uptrend where the price is trading 69.2% above its 200 day moving average.
From a valuation standpoint, the stock is 97.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 28.1.
Sesen Bio, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 55.3% to $-15M since the same quarter in the previous year.
Finally, its free cash flow grew by 38.4% to $-9M since the same quarter in the previous year.
Based on the above factors, Sesen Bio, Inc gets an overall score of 4/5.